Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOT101 in combination with pembrolizumab for selected advanced or refractory solid tumors
2021-005774-25Phase 2Completed
- Sponsor
- SOTIO Biotech
- Start
- Mar 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nanrilkefusp alfa and pembrolizumab in Nonhematologic neoplasms and non-small cell lung cancer (NSCLC), sponsored by SOTIO Biotech. Primary endpoint: Objective response rate. Started Mar 2022; status: completed.
02
Drugs
nanrilkefusp alfapembrolizumab
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2021-005774-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005774-25.